StockData
Biohaven Ltd. logo

Biohaven Ltd. (BHVN) company profile

BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$12.90−0.34 (-2.57%)

Close on Nov 18, 2026Market cap $1.95BP/E –Yield –

About Biohaven

Pharmaceutical Preparations, SIC 2834

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, immunological, and metabolic conditions. The company advances several clinical-stage drug candidates across multiple therapeutic platforms. Key investigational assets include BHV-1300 and BHV-1400, which are extracellular protein degraders under development for autoimmune diseases such as Graves' disease and IgA nephropathy. It also develops opakalim, a potassium channel activator for epilepsy, and taldefgrobep alfa, an investigational agent targeting obesity and neuromuscular disorders. Biohaven's potential treatments are designed for patients affected by serious central nervous system, autoimmune, and metabolic disorders.

Biohaven controls worldwide rights to substantially all of its product candidates and operates on an international scale. Its clinical research network includes more than 110 global clinical trial sites selected for its focal epilepsy program, alongside clinical evaluations approved in Canada. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Biohaven's latest annual report, written by StockData.

Company profile

Company

Legal name
Biohaven Ltd.
Headquarters
New Haven, CT
Address
215 Church Street 06510
Phone
(203) 404-0410
Employees
274, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
D8
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Stamford, Connecticut

Stock & identifiers

Ticker
BHVN
Exchange
NYSE
IPO date
Sep 23, 2022
Shares outstanding
151M, Oct 26, 2026
Public float
$1.04B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1935979
CUSIP
G1110E107
FIGI
BBG017BXV3Q9
Share class FIGI
BBG017BXV3R8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Vlad CoricChief Executive Officer, Director3,856,784
Kimberly GentileSVP, Clinical Operations101,513
Warren Karl VollesChief Legal Officer248,212
George C. ClarkVP, Chief Accounting Officer86,978
Bruce CarChief Scientific Officer40,096
Matthew ButenChief Financial Officer198,246
John YetimogluDirector6,250,000
Gregory BaileyDirector2,020,071
John W. ChildsDirector8,088,392
Kishan MehtaDirector22,662
Irina AntonijevicDirector2,535
Michael Thomas HeffernanDirector15,178
Robert J. HuginDirector12,959
Julia P. GregoryDirector25,665

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.50M-$3.87M$4.42M$166$152
FY2024$10.48M$9.85M$3.94M$534$113
FY2023$6.82M$22.15M$2.63M$611$112
FY2022$5.97M$9.97M$1.91M$198$104

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Vlad Coric
Chief Executive Officer
$920.40K$460.20K$2.20M$9.90M$17.32K$13.50M+29%
Matthew Buten
Chief Financial Officer
$596.23K$238.49K$656.88K$3.00M$23.89K$4.52M+12%
Kimberly Gentile
Senior Vice President, Clinical Operations
$508.88K$229.00K$579.60K$2.63M$19.85K$3.96M+3%
Bruce Car
Chief Scientific Officer
$536.19K$241.29K$734.16K$3.23M$23.89K$4.77M+21%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“Development and continuous feedback are priorities for our organization, which was comprised of 274 employees as of December 31, 2025.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 14, 2022Name changeName changed from Biohaven Research Ltd. to Biohaven Ltd.
Aug 10, 2022Spin-offRegistration as a new public company (Form 10), e.g. spin-off

See a number that looks wrong?